AC Immune (ACIU) Net Income towards Common Stockholders (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.10% |
| Dec 31, 2025 | 9.29% |
| Sep 30, 2025 | 22.54% |
| Jun 30, 2025 | -20.93% |
| Mar 31, 2025 | -17.39% |
| Dec 31, 2024 | -383.85% |
| Sep 30, 2024 | 125.24% |
| Jun 30, 2024 | -22.98% |
| Mar 31, 2024 | -282.80% |
| Dec 31, 2023 | 68.81% |
| Sep 30, 2023 | 8.43% |
| Jun 30, 2023 | 1.13% |
| Mar 31, 2023 | 2.72% |
| Dec 31, 2022 | -39.11% |
| Sep 30, 2022 | 31.40% |
| Jun 30, 2022 | 0.05% |
| Mar 31, 2022 | 11.58% |
| Dec 31, 2021 | -33.07% |
| Sep 30, 2021 | 17.10% |
| Jun 30, 2021 | -14.60% |
| Mar 31, 2021 | 15.40% |
| Dec 31, 2020 | -4.53% |
| Sep 30, 2020 | -26.34% |
| Jun 30, 2020 | -147.51% |
| Mar 31, 2020 | 66.41% |
| Dec 31, 2019 | -206.29% |
| Sep 30, 2019 | 209.68% |
| Jun 30, 2019 | -126.40% |
| Mar 31, 2019 | 532.79% |
| Dec 31, 2018 | -7.36% |
| Sep 30, 2018 | -21.35% |
| Jun 30, 2018 | 7.55% |
| Mar 31, 2018 | -390.15% |
| Dec 31, 2017 | 145.12% |
| Sep 30, 2017 | -12.38% |
| Jun 30, 2017 | 11.62% |
| Mar 31, 2017 | -97.54% |
| Dec 31, 2016 | 41.14% |
| Sep 30, 2016 | -162.86% |
| Jun 30, 2016 | 307.20% |
| Mar 31, 2016 | -10.19% |
| Dec 31, 2015 | -127.05% |